147 related articles for article (PubMed ID: 33991409)
41. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
42. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
[TBL] [Abstract][Full Text] [Related]
43. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
[TBL] [Abstract][Full Text] [Related]
44. MiR-590 Suppresses Proliferation and Induces Apoptosis in Pancreatic Cancer by Targeting High Mobility Group A2.
Wang YD; Mao JD; Wang JF; Xu MQ
Technol Cancer Res Treat; 2020; 19():1533033820928143. PubMed ID: 32588766
[TBL] [Abstract][Full Text] [Related]
45. Hypoxia-Induced TGFBI as a Serum Biomarker for Laboratory Diagnosis and Prognosis in Patients with Pancreatic Ductal Adenocarcinoma.
Yang L; Cui R; Li Y; Liang K; Ni M; Gu Y
Lab Med; 2020 Jul; 51(4):352-361. PubMed ID: 31626700
[TBL] [Abstract][Full Text] [Related]
46. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals.
Kulkarni NM; Mannelli L; Zins M; Bhosale PR; Arif-Tiwari H; Brook OR; Hecht EM; Kastrinos F; Wang ZJ; Soloff EV; Tolat PP; Sangster G; Fleming J; Tamm EP; Kambadakone AR
Abdom Radiol (NY); 2020 Mar; 45(3):729-742. PubMed ID: 31768594
[TBL] [Abstract][Full Text] [Related]
47. Expression of Calretinin, Marker of Mesothelial Differentiation, in Pancreatic Ductal Adenocarcinoma: A Potential Diagnostic Pitfall.
Askan G; Basturk O
Turk Patoloji Derg; 2021; 37(2):115-120. PubMed ID: 33432559
[TBL] [Abstract][Full Text] [Related]
48. Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma.
Sharma GG; Okada Y; Von Hoff D; Goel A
Semin Cancer Biol; 2021 Oct; 75():153-168. PubMed ID: 33049362
[TBL] [Abstract][Full Text] [Related]
49. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature.
Davis VW; Schiller DE; Eurich D; Bathe OF; Sawyer MB
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S415-23. PubMed ID: 23096698
[TBL] [Abstract][Full Text] [Related]
50. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.
Chang DZ; Ma Y; Ji B; Liu Y; Hwu P; Abbruzzese JL; Logsdon C; Wang H
J Hematol Oncol; 2012 Apr; 5():15. PubMed ID: 22475564
[TBL] [Abstract][Full Text] [Related]
51. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease.
Wang J; Chen J; Chang P; LeBlanc A; Li D; Abbruzzesse JL; Frazier ML; Killary AM; Sen S
Cancer Prev Res (Phila); 2009 Sep; 2(9):807-13. PubMed ID: 19723895
[TBL] [Abstract][Full Text] [Related]
52. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
[TBL] [Abstract][Full Text] [Related]
53. Autophagy Regulatory Genes MET and RIPK2 Play a Prognostic Role in Pancreatic Ductal Adenocarcinoma: A Bioinformatic Analysis Based on GEO and TCGA.
Li X; Li Z; Zhu H; Yu X
Biomed Res Int; 2020; 2020():8537381. PubMed ID: 33204717
[TBL] [Abstract][Full Text] [Related]
54. Association of chloride intracellular channel 4 and Indian hedgehog proteins with survival of patients with pancreatic ductal adenocarcinoma.
Zou Q; Yang Z; Li D; Liu Z; Yuan Y
Int J Exp Pathol; 2016 Dec; 97(6):422-429. PubMed ID: 28205343
[TBL] [Abstract][Full Text] [Related]
55. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
Chu PG; Schwarz RE; Lau SK; Yen Y; Weiss LM
Am J Surg Pathol; 2005 Mar; 29(3):359-67. PubMed ID: 15725805
[TBL] [Abstract][Full Text] [Related]
56. Pancreatic ductal adenocarcinoma: Prognostic indicators of advanced disease.
Kruger D; Lahoud N; Yako YY; Devar J; Smith M
PLoS One; 2022; 17(1):e0262439. PubMed ID: 35020761
[TBL] [Abstract][Full Text] [Related]
57. Expression of cathepsin E in pancreas: a possible tumor marker for pancreas, a preliminary report.
Azuma T; Hirai M; Ito S; Yamamoto K; Taggart RT; Matsuba T; Yasukawa K; Uno K; Hayakumo T; Nakajima M
Int J Cancer; 1996 Aug; 67(4):492-7. PubMed ID: 8759606
[TBL] [Abstract][Full Text] [Related]
58. Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients.
Martinez-Useros J; Li W; Georgiev-Hristov T; Fernandez-Aceñero MJ; Borrero-Palacios A; Perez N; Celdran A; Garcia-Foncillas J
Pathol Oncol Res; 2019 Jan; 25(1):269-278. PubMed ID: 29101736
[TBL] [Abstract][Full Text] [Related]
59. Expression and clinical significance of placenta-specific 1 in pancreatic ductal adenocarcinoma.
Yin Y; Zhu X; Huang S; Zheng J; Zhang M; Kong W; Chen Q; Zhang Y; Chen X; Lin K; Ouyang X
Tumour Biol; 2017 Jun; 39(6):1010428317699131. PubMed ID: 28618924
[TBL] [Abstract][Full Text] [Related]
60. Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients.
Blyuss O; Zaikin A; Cherepanova V; Munblit D; Kiseleva EM; Prytomanova OM; Duffy SW; Crnogorac-Jurcevic T
Br J Cancer; 2020 Mar; 122(5):692-696. PubMed ID: 31857725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
